BC Cancer Agency

What BC Cancer Agency does

Canada's Michael Smith Genome Sciences Centre (GSC), operating as a provincial program within the BC Cancer Agency and the Provincial Health Services Authority (PHSA) of British Columbia, is a publicly funded genomics research and clinical services organization founded in 1999 and headquartered in Vancouver at 675 West 10th Avenue. Its mandate spans the full continuum of cancer care and broader life sciences, providing high-throughput DNA sequencing, bioinformatics analysis, and clinical genomic panel testing to academic investigators, oncologists, pathologists, and patients across British Columbia and partner institutions worldwide. The GSC integrates research and clinical practice through flagship programs including the Personalized OncoGenomics (POG) program, which applies whole genome and transcriptome sequencing to guide therapeutic decision-making for advanced cancer patients, and the Centre for Clinical Genomics, Canada's first CAP-accredited laboratory to use next generation sequencing for cancer diagnostics.

The GSC's technology stack combines cutting-edge sequencing platforms with a substantial in-house software portfolio, including the ABySS parallel genome assembler, Circos data visualization tool, the ChIP-seq technique, clonealign and ddClone for single-cell integrative analysis, Direct Library Preparation (DLP), and the PORI open-source precision oncology reporting platform. It holds CAP, DAP, and ISO/IEC 27001 certifications, and operates within national infrastructure including the Pan-Canadian Genome Library, the Canadian Genome-Phenome Archive, CGEn, the Marathon of Hope Cancer Centres Network, and Federated EGA. The organization has sequenced over 6 quadrillion bases across more than 350 species, reached 3 petabytes of sequencing data, and developed collaborations across TCGA, IHEC, MAGIC, Earth BioGenome, and the Silent Genomes Project.

Commercially, the GSC operates as a collaborative research services organization rather than a product vendor, delivering sequencing, bioinformatics, proteomics, digital pathology with machine learning, and drug discovery services through direct investigator collaboration, service request forms, and promotional technology partnerships (Olink, 10x Genomics, Swiss Vault). Funding flows primarily through PHSA provincial appropriations, with additional capital from Genome Canada ($81M CPHI), federal grants ($15M PCGL), Genome British Columbia ($1.25M Northern Biobank), and the BC Cancer Foundation. The October 2025 mandate expansion into environmental, agricultural, and industrial genomics signals a strategic broadening beyond the original clinical and cancer focus.

Name

BC Cancer Agency

Legal name

Provincial Health Services Authority

Website

https://bcgsc.ca

Company type

Private

Founded year

1999

Operating status

Operating

Headcount range

1–10 employees

Short description

Canada's Michael Smith Genome Sciences Centre, a provincial program within BC Cancer and the Provincial Health Services Authority, delivers genomics sequencing, bioinformatics, and accredited clinical genomic testing to academic researchers, oncologists, and cancer patients in British Columbia.

Ownership category

akta.pro rank

Product category

Clinical Genomics Services

NAICS

Medical Laboratories (621511), Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Genomics & Next-Generation Sequencing (NGS) Services (HLAGANAA)

akta.pro secondary industries

Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF), Transcriptomics & Gene Expression Profiling Services (HLAGANAE), Molecular Tumor Boards & Clinical Interpretation Services (HLAAANAD)

Keywords

• Clinical genomics services
• Cancer genomic sequencing
• Bioinformatics data analysis
• Precision oncology testing
• Translational genomic research

Headquarters

HQ city

Vancouver

HQ country

Canada

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

1. Provincial Health Services Authority Funding: As a provincial program within PHSA, the GSC operates as a publicly funded research institution providing genomics services to the healthcare system and research community

Go-to-market motion1 record

Distribution channels1 record

Marketing channels8 records

Core offering

Canada's Michael Smith Genome Sciences Centre (GSC), a provincial program within BC Cancer, provides high-throughput DNA sequencing, whole genome and transcriptome analysis, clinical genomic panel testing, and advanced bioinformatics services. The core offerings include the Personalized OncoGenomics (POG) program for cancer treatment guidance, the CAP/DAP-accredited Centre for Clinical Genomics for diagnostic testing, and collaborative sequencing and computational analysis services for academic, clinical, and industry researchers.

Product overview

Canada's Michael Smith Genome Sciences Centre operates as a provincial program within BC Cancer's Provincial Health Services Authority, offering an integrated suite of genomics services centered around clinical and research operations. The core offerings include the Personalized OncoGenomics (POG) Program for cancer treatment guidance through whole genome/transcriptome analysis, the Centre for Clinical Genomics for CAP-accredited diagnostic testing, and comprehensive sequencing and bioinformatics services. Supporting modules include drug discovery, proteomics, digital pathology with AI-powered tumor identification, and the open-source PORI reporting platform. The organization provides technology platforms for scalable genomic data generation and analysis, supported by an extensive software portfolio including ABySS assembler and Circos visualization tools. Services are delivered through collaborative partnerships with academic and clinical institutions across Canada.

Differentiator

Problem solved

Functional benefit

Products and services

• Personalized OncoGenomics (POG) Program Clinical research initiative applying whole genome and transcriptome sequencing to guide therapeutic decision-making for patients with advanced cancers. Provides data-driven genomic explanations for treatment failure and identifies potential therapeutic targets.
• Centre for Clinical Genomics (CCG) First College of American Pathologists (CAP) certified laboratory in Canada to use next-generation sequencing technologies for cancer diagnostics. Accredited for clinical genomic panel testing with reduced patient wait times for genetic testing.
• Sequencing Services Cutting-edge DNA sequencing technologies and services for processing complex and high-value biological samples with expert support for experimental design and technology development.
• Bioinformatics Data Analysis Services Advanced bioinformatics services providing computational analysis of genomic, transcriptomic, and proteomic data with expertise in genome assembly, variant calling, and biological interpretation.
• Clinical Genomic Panel Testing Accredited clinical genomic testing services for cancer diagnostics supporting precision medicine initiatives across British Columbia.
• Digital Pathology Project Project to collect 10,000 pathology slides from up to 30 different cancer types with infrastructure for automated clinical data handling, online slide annotation, and machine learning support for automated tumor identification.
• Drug Discovery Services Collaborative drug discovery services supporting therapeutic development including novel prostate cancer therapeutics research through the Sadar lab's work on androgen receptor N-terminal domain antagonists.
• Proteomics Services Proteomic analysis services led by Dr. Gregg Morin, Head of Proteomics at BC Cancer, providing protein analysis capabilities integrated with genomic research.
• PORI - Platform for Oncogenomic Reporting and Interpretation Open-source interpretation and reporting platform for precision oncology that integrates multiple knowledge bases for sharing genome analysis data related to precision oncology.
• Collaborative Research Services Expert support for experimental design, technology development, and collaborative discovery for investigators including sample processing, advanced sequencing, and bioinformatics analysis.

Quantifiable outcome

• Whole genome and transcriptome analysis impacts treatment options and clinical management for patients in BC Cancer's Personalized OncoGenomics Program
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration7 records

AI capability8 records

Feature9 records

Partnerships

17 partnerships are on record, tiered core and minor.

• Federated European Genome-Phenome Archive (Federated EGA)coreStrategic or Co-development Partner · 1 April 2025Canadian Genome-Phenome Archive (CGA), part of Pan-Canadian Genome Library (PCGL), joined Federated EGA marking the federation's first significant expansion outside of Europe for secure sharing of human genomic and health data.
• Canadian Precision Health Initiative (CPHI)coreStrategic or Co-development Partner · 5 March 2025GSC is collaborating on five groundbreaking projects as part of CPHI, an $81-million national investment from the Government of Canada through Genome Canada. The initiative aims to sequence 100,000 genomes reflective of Canada's diverse population for precision health.
• Genome BC GeneskoolminorGTM or Marketing Partner · 1 September 2024GSC partners with Genome BC's Geneskool to bring real-world genomics into the classroom as educational tours resume for students and teachers.
• Pan-Canadian Genome Library (PCGL)coreStrategic or Co-development Partner · 1 December 2023First-of-its-kind Pan-Canadian Genome Library representing an $15 million investment from the Government of Canada to advance genomic research infrastructure.
• Marathon of Hope Cancer Centres NetworkcoreStrategic or Co-development Partner · 1 July 2019GSC joined the Marathon of Hope Cancer Centres Network with the goal of advancing precision medicine by working collaboratively and sharing data.
• Silent Genomes ProjectminorStrategic or Co-development Partner · 1 July 2018Project aims to reduce health care disparities and improve diagnostic success for children with genetic diseases from Indigenous populations. Dr. Nadine Caron leads the project.
• CanSeq150minorStrategic or Co-development Partner · 1 January 2017Initiative to sequence genomes of 150 iconic Canadian species as part of Canada's 150th anniversary. GSC has sequenced beluga whale, grizzly bear, sea otter, sea lion and others.
• Medulloblastoma Advanced Genomics International Consortium (MAGIC)minorStrategic or Co-development Partner · 1 January 2012International consortium using genome science to define and understand subgroups of medulloblastoma, the most common childhood brain cancer.
• The Cancer Genome Atlas (TCGA)coreStrategic or Co-development Partner · 1 January 2006GSC was the only international participant in TCGA, a landmark project characterizing tumours from 33 different cancer types. GSC scientists received Team Science Award from AACR for contributions.
• University of British ColumbiacoreStrategic or Co-development PartnerGSC faculty hold appointments in various Departments of UBC. Faculty members include professors in Medical Genetics, Microbiology and Immunology, and other departments. GSC is part of Michael Smith Laboratories.
• Simon Fraser UniversitycoreStrategic or Co-development PartnerGSC faculty hold appointments in various Departments of Simon Fraser University, including Molecular Biology and Biochemistry and Biomedical Physiology and Kinesiology.
• Lower Mainland Pathology & Laboratory Medicine ServicescoreImplementation/ SI/ Consulting PartnerPartnership with clinical laboratories of Lower Mainland Pathology & Laboratory Medicine Services provides extensive diagnostic experience and consultation for Centre for Clinical Genomics.
• BC Cancer FoundationcoreGTM or Marketing PartnerBC Cancer Foundation is the fundraising partner of BC Cancer, which includes BC Cancer Research. Together with donors, they fund innovative research and personalized treatment and care.
• Terry Fox Research InstitutecoreStrategic or Co-development PartnerGSC participates in TFRI B.C. Node activities and joined the Marathon of Hope Cancer Centres Network. GSC scientists contribute to TFRI Program Project in acute leukemia research led by Dr. Karsan.
• CGEn (Canadian Genome Engineering Centre)coreStrategic or Co-development PartnerGSC is one of three nodes in Canada's national platform for genome sequencing and analysis (CGEn), enabling participation in national genomics initiatives.
• Earth BioGenome ProjectminorStrategic or Co-development PartnerGSC joined the Earth BioGenome Secretariat as part of commitment to advancing genomics and biodiversity conservation.
• International Human Epigenome Consortium (IHEC)coreStrategic or Co-development PartnerGSC contributed to analysis of over 111 reference human epigenomes published in Nature under IHEC leadership.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Broad Institute: US-based genomics and biomedical research organization operating large sequencing platforms, clinical genomics pipelines, and widely used computational tools (e.g., GATK). Highly comparable to GSC's mix of high-throughput sequencing, computational biology, and translational research.
• New York Genome Center: Clinical and research genomics center providing CAP-accredited clinical sequencing, large-scale research collaborations, and bioinformatics services in a public-nonprofit model. Closely parallels GSC's POG-style clinical integration and academic-industry partnership model.
• Wellcome Sanger Institute: World-leading genomics institute delivering large-scale sequencing, cancer genomics (e.g., PCAWG), and open-source bioinformatics tools. Comparable to GSC in operating at genome-scale, contributing to international consortia, and running clinically linked research programs.
• HudsonAlpha Institute for Biotechnology: Non-profit genomics and clinical sequencing center offering CAP/CLIA-accredited clinical diagnostics, research services, and technology development. Overlaps with GSC in combining clinical genomic testing with discovery research under a single institute.
• Baylor College of Medicine Human Genome Sequencing Center: Major US academic sequencing center contributing to large-scale initiatives (Human Genome Project, TOPMed, Centers for Mendelian Genomics). Comparable to GSC in operating production-scale sequencing and clinical genomics collaborations.
• Ontario Institute for Cancer Research: Canadian cancer genomics research institute that, like GSC, combines large-scale sequencing, bioinformatics, and clinical translation within a publicly funded mandate. OICR is the closest domestic peer with overlapping programs in precision oncology and molecular tumor profiling.
• Translational Genomics Research Institute (TGen): Non-profit genomics institute focused on clinical translation in oncology, infectious disease, and rare disease, with CLIA-certified clinical sequencing. Highly comparable mission and operating model to GSC's precision-oncology focus.
• J. Craig Venter Institute: Non-profit genomics research institute that pioneered large-scale sequencing (e.g., first diploid human genome) and continues to run high-throughput sequencing and synthetic biology programs. Comparable to GSC in being a science-first, non-profit sequencing powerhouse.

Regional players

• Garvan Institute of Medical Research: Australian medical research institute with major programs in clinical genomics, whole-genome sequencing (e.g., Genome.One), and precision medicine. Comparable mandate and operating model, but geographically focused on Australia rather than Canada.
• Genome Institute of Singapore: National genomics institute within A*STAR that delivers large-scale sequencing, single-cell genomics, and clinical translation in Asia. Similar public-mandate, high-throughput sequencing operating model, but with a regional rather than Canadian catchment.

Market position

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/GSCofBC
• LinkedInlinkedin.com/company/michael-smith-genome-sciences-centre

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BC Cancer Agency